A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based…
India’s largest drug maker Sun Pharmaceutical Industries has launched its global innovative drug Ilumya (tildrakizumab) in the country, the company said in an announcement on Monday. Ilumya is used in the treatment of plaque psoriasis. “Ilumya offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,” said…
Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA (Tildrakizumab) has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis….
No Trial Waiver: CDSCO Panel Directs Sun Pharma to Run Phase III Study for Somatropin Liquid Injection Citing Lack of India-Specific Data We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie…
New Delhi: Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd‘s proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs…
Sun Pharma Wins Interim Relief in NAXDOM Trademark Row, Delhi HC Bars Alenvision’s NEXADOM Drug We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Sun Pharma Told to Limit Phase III Revefenacin Study to Triple Therapy COPD Patients We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Enzalutamide for Prostate Cancer We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Sun Pharma Wins CDSCO Panel Approval for Phase III Vitiligo Trial of Ruxolitinib Cream We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Drug makers Glenmark, Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company,…